Extended regimens of the contraceptive vaginal ring versus hormonal oral contraceptives: effects on lipid metabolism

被引:12
作者
Falbo Guazzelli, Cristina Aparecida [1 ]
Barreiros, Fernando Augusto [1 ,2 ]
Barbosa, Ricardo [3 ]
Torloni, Maria Regina [1 ]
Barbieri, Marcia [1 ]
机构
[1] Sao Paulo Fed Univ UNIFESP, Dept Obstet & Gynecol, Family Planning Clin, Sao Paulo, Brazil
[2] Western Univ Sao Paulo UNOESTE, Dept Gynecol & Obstet, Presidente Prudente, Brazil
[3] Univ Sao Paulo, Dept Nursing, Sao Paulo, Brazil
关键词
Hormonal contraceptive; Lipids-cholesterol; Hormonal metabolic; Contraceptive vaginal; Extended cycle; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; APOLIPOPROTEIN-A-I; 30; MU-G; ETHINYL ESTRADIOL; CARDIOVASCULAR-DISEASE; CARBOHYDRATE-METABOLISM; DESOGESTREL; RISK; PLASMA;
D O I
10.1016/j.contraception.2011.08.014
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: Combined oral contraceptives used in an extended regimen have been studied because of their potential benefits; however, there have been few publications on extended regimens of contraceptive vaginal rings. The aim of this study was to assess the effects of these two extended regimens on the lipid metabolism of women using these contraceptive methods during 1 year. Study Design: This prospective study enrolled 150 women: 75 used a vaginal contraceptive ring (11.7 mg etonogestrel and 2.7 mg ethinyl estradiol), and 75 used oral contraceptives (30 mcg ethinyl estradiol and 150 mg desogestrel). Both groups used their respective method for 84 days followed by a 7-day pause during I year. At baseline and every 3 months during the study period, blood was collected to assess total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides and apolipoprotein (apo) A-I and B. The analysis of variance test was used to analyze differences in the results of these exams over time. Results: A total of 62 vaginal ring and 61 oral contraceptive users completed the study. There were no significant differences in the discontinuation rate, mean total cholesterol and fraction levels, apo B concentration or apo A-I/apo B ratio. Vaginal ring users had significantly higher apo A-I levels than oral contraceptive users. Conclusion: Despite the vaginal route of administration, the steroids released by the ring had the same effects on the lipid metabolism and lipoprotein levels typically seen with ethinyl estradiol given either by oral or parenteral routes. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:389 / 393
页数:5
相关论文
共 25 条
[1]   ORAL-CONTRACEPTIVE TABLETS CONTAINING 20 AND 30 MU-G OF ETHINYL ESTRADIOL WITH 150 MU-G DESOGESTREL - THEIR INFLUENCE ON LIPIDS, LIPOPROTEINS, SEX-HORMONE BINDING GLOBULIN AND TESTOSTERONE [J].
AKERLUND, M ;
ALMSTROM, E ;
HOGSTEDT, S ;
NABRINK, M .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1994, 73 (02) :136-143
[2]  
[Anonymous], 2008, MED EL CRIT CONTR US
[3]   Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism [J].
Barreiros, Fernando Augusto ;
Falbo Guazzelli, Cristina Aparecida ;
Barbosa, Ricardo ;
Torloni, Maria Regina ;
Barbieri, Marcia ;
Araujo, Fabio F. .
CONTRACEPTION, 2011, 84 (02) :155-159
[4]   Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel [J].
Barter, PJ ;
Ballantyne, CM ;
Carmena, R ;
Cabezas, MC ;
Chapman, MJ ;
Couture, P ;
De Graaf, J ;
Durrington, PN ;
Faergeman, O ;
Frohlich, J ;
Furberg, CD ;
Gagne, C ;
Haffner, SM ;
Humphries, SE ;
Jungner, I ;
Krauss, RM ;
Kwiterovich, P ;
Marcovina, S ;
Packard, CJ ;
Pearson, TA ;
Reddy, KS ;
Rosenson, R ;
Sarrafzadegan, N ;
Sniderman, AD ;
Stalenhoef, AF ;
Stein, E ;
Talmud, PJ ;
Tonkin, AM ;
Walldius, G ;
Williams, KMS .
JOURNAL OF INTERNAL MEDICINE, 2006, 259 (03) :247-258
[5]   Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin [J].
Crook, D .
CONTRACEPTION, 1997, 55 (04) :219-224
[6]   ORAL-CONTRACEPTIVES AND CORONARY HEART-DISEASE - MODULATION OF GLUCOSE-TOLERANCE AND PLASMA-LIPID RISK-FACTORS BY PROGESTINS [J].
CROOK, D ;
GODSLAND, IF ;
WYNN, V .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1988, 158 (06) :1612-1620
[7]   Increased Apolipoprotein AI Production Rate and Redistribution of High-Density Lipoprotein Size Induced by Estrogen plus Progestin as Oral Contraceptive [J].
Duvillard, Laurence ;
Dautin, Guillaume ;
Florentin, Emmanuel ;
Jeannin, Aline ;
de Barros, Jean-Paul Pais ;
Lagrost, Laurent ;
Petit, Jean-Michel ;
Gambert, Philippe ;
Verges, Bruno .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (12) :4891-4897
[8]   The recent saga of cardiovascular disease and safety of oral contraceptives [J].
Edwards, RG ;
Cohen, J .
HUMAN REPRODUCTION UPDATE, 1999, 5 (06) :565-620
[9]   Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size [J].
Foulon, T ;
Payen, N ;
Laporte, F ;
Bijaoui, S ;
Dupont, G ;
Roland, F ;
Groslambert, P .
CONTRACEPTION, 2001, 64 (01) :11-16
[10]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499